Immunology of malaria

Essential Malariology, Fourth Edition

Volumn , Issue , 2017, Pages 252-267

  Marsh, Kevin ^a,b  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85053979058     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780203756621     Document Type: Chapter

References (33)

1. Adam C, Geniteau M, Gougerot-Pocidalo M, etal. Cryoglobulins, circulating immune complexes, and complement activation in cerebral malaria. Infect Immun 1981; 31: 530-5.
2. Alonso PL, Smith T, Schellenberg JR, etal. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 1994; 344: 1175-81.
3. Anders RF. Multiple cross-reactivities amongst antigens of Plasmodium falciparum impair the development of protective immunity against malaria. Parasite Immunol 1986; 8: 529-39.
4. Baird JK. Age-dependent characteristics of protection v. susceptibility to Plasmodium falciparum. Ann Trop Med Parasitol 1998; 92: 367-90.
5. Bates I, Bedu-Addo G, Rutherford TR, Bevan DH. Circulating villous lymphocytes - a link between hyperreactive malarial splenomegaly and splenic lymphoma. Trans R Soc Trop Med Hyg 1997; 91; 171-4.
6. Bayoumi RA. The sickle-cell trait modifies the intensity and specificity of the immune response against P falciparum malaria and leads to acquired protective immunity. Med Hypoth 1987; 22: 287-98.
7. Berkley J, Mwarumba S, Bramham K, Lowe B, Marsh K. Bacteraemia complicating severe malaria in children. Trans R Soc Trop Med Hyg 1999; 93: 283-6.
8. Bull PC, Lowe BS, Kortok M, Molyneux CS, Newbold Cl, Marsh K. Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nat Med 1998; 4: 358-60.
9. Crane GG, Wells JV, Hudson P. Tropical splenomegaly syndrome in New Guinea. I. Natural history. Trans R Soc Trop Med Hyg 1972; 66: 724-32.
10. D’Alessandro U, Leach A, Drakeley CJ, etal. Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet 1995; 346: 462-7.
11. Daniel-Ribeiro C, Ben Slama L, Gentilini M. Anti-nuclear and anti-smooth muscle antibodies in Caucasians, Africans and Asians with acute malaria. J Clin Lab Immunol 1991; 35:109-12.
12. Fernandez-Reyes D, Craig AG, Kyes SA, et al. A high frequency African coding polymorphism in the N-terminal domain of ICAM-1 predisposing to cerebral malaria in Kenya. Hum Mol Genet 1997; 6: 1357-60.
13. Flint J, Hill AV, Bowden DK, etal. High frequencies of alpha-thalassaemia are the result of natural selection by malaria. Nature 1986; 321: 744-50.
14. Fried M, Nosten F, Brockman A, Brabin BJ, Duffy PE. Maternal antibodies block malaria. Nature 1998; 395: 851-2.
15. Good MF, Doolan DL. Immune effector mechanisms in malaria. Curr Opin Immunol 1999; 11: 412-9.
16. Greenwood BM, Brueton MJ. Complement activation in children with acute malaria. Clin Exp Immunol 1974; 18: 267-72.
17. Greenwood BM, Herrick EM, Voller A. Suppression of autoimmune disease in NZB and (NZB X NZW) F1 hybrid mice by infection with malaria. Nature 1970; 226: 266-7.
18. Gupta S, Snow RW, Donnelly CA, Marsh K, Newbold C. Immunity to non-cerebral severe malaria is acquired after one or two infections. Nat Med 1999; 5: 340-3.
19. Hendrickse RG, Adeniyi A, Edington GM, Glasgow EF, White RH, Houba V. Quartan malarial nephrotic syndrome. Collaborative dinicopathological study in Nigerian children. Lancet 1972; 1:1143-9.
20. Hill AV, Allsopp CE, Kwiatkowski D, etal. Common west African HLA antigens are associated with protection from severe malaria. Nature 1991; 352: 595-600.
21. Kaslow DC. Transmission-blocking vaccines: uses and current status of development. Int J Parasitol 1997; 27:183-9.
22. Knight JC, Udalova I, Hiw AL, etal. A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria. Nat Genet 1999; 22: 145-50.
23. Kyes SA, Rowe JA, Kriek N, Newbold Cl. Rifins: a second family of donally variant proteins expressed on the surface of red cells infected with Plasmodium falciparum. Proc Nat Acad Sei USA 1999; 96: 9333-8.
24. Miller LH, Good MF, Kaslow DC. Vaccines against the blood stages of falciparum malaria. Adv Exp Med Biol 1998; 452: 193-205.
25. Newbold Cl, Craig AG, Kyes S. etal. PfEMP-1, polymorphism and pathogenesis. Ann Trop Med Parasitol 1997; 91: 551-7.
26. Pasvol G, Weatherall DJ. The red cell and the malarial parasite. BrJ Haematol 1980; 46:165-70.
27. Ruwende C, Khoo SC, Snow RW, etal. Natural seledion of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria. Nature 1995; 376: 246-9.
28. Stoute JA, Slaoui M, Heppner DG, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTSS Malaria Vaccine Evaluation Group. N Engl f Med 1997; 336: 86-91.
29. Träger W, Jensen JB. Continuous culture of Plasmodium falciparum: its impad on malaria research. Int J Parasitol 1997; 27: 989-1006.
30. Weatherall DJ, Abdalla S, Pippard MJ. The anaemia of Plasmodium falciparum malaria. Ciba Found Symp 1983; 94: 74-97.
31. Weatherall DJ. Common genetic disorders of the red cell and the 'malaria hypothesis'. Ann Trap Med Parasitol 1987; 81; 539-518.
32. Whittle HC, Brown J, Marsh K, Blackman M, Jobe O, Shenton F. The effects of Plasmodium falciparum malaria on immune control of B lymphocytes in Gambian children. Clin Exp Immunol 1990; 80: 213-18.
33. Williams TN, Maitland K, Bennett S, etal. High incidence of malaria in alpha-thalassaemic children. Nature 1996; 383 522-5.